Project Grant K08CA308845
Award Date 7/15/26
Completion Date 6/30/31
Dollars Obligated $212K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40202, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Louisville Office of Research & Innovation a $403,686 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, through April 30, 2028, to develop and evaluate a novel combination therapy for recurrent ovarian cancer. The research addresses a critical clinical need: approximately 70% of ovarian cancer patients develop platinum-resistant recurrence within 18–24 months...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $100,228 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2026, through April 30, 2028. The award funds research and development of a verifiable and robust deformable image registration (DIR) method designed to improve precision tracking of diffuse glioma progression, particularly glioblastoma (GBM). The project addresses...
- Federal Grant Award Summary Georgetown University received a $429,000 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on April 16, 2026, with a completion date of March 31, 2028. The award supports research into epigenetic biomarkers in glioblastoma (GBM), the most common malignant primary brain tumor in adults. The project focuses on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $707,798 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning April 1, 2026, and concluding March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-resistant form within months of standard-of-care treatment. The primary deliverable is...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88M Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on September 23, 2025, with completion targeted for August 31, 2029. The award funds research integrating genome-wide association study (GWAS) data with single-cell omics technologies to identify cellular effectors of glioblastoma predisposition. This research aims to advance...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $429,000 to the University of Michigan's Office of Research and Sponsored Projects, effective August 1, 2025, through July 31, 2027, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research project investigates the mechanism of Notch inhibition resistance in glioblastoma (GBM) stem cells to develop novel...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $645,185 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, with completion anticipated by April 30, 2031. This award supports research to develop and evaluate a novel combination immunotherapy approach for glioblastoma, a highly aggressive brain tumor with poor patient survival outcomes. The project, titled "Expand and Pull: Long-Acting IL-7 and Oncolytic...
- Federal Grant Award Summary The National Cancer Institute awarded Albert Einstein College of Medicine a $431,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 24, 2026, to advance immunotherapy approaches for treating glioblastoma multiforme (GBM), a particularly aggressive form of brain cancer. The project, scheduled for completion by May 31, 2028, focuses on developing and validating a Listeria-based immunotherapy delivery system combined with gemcitabine...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Mayo Clinic a $954,256 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 18, 2025, through July 31, 2030. This research initiative applies germline and somatic genetic analysis to elucidate glioma risk and improve patient outcomes. The project leverages genome-wide association studies (GWAS) identifying 30 germline variants associated with adult diffuse glioma risk, examining...